1[1]Daniel J H,Francesco MM,Soldano F.HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story[J].Mol Med Today,1999,5: 178-186.
2[2]Alessandro S,Robert C,John F.HLA expression in cancer: Implications for T cell-based immunotherapy [ J ].Immunogenetics,2001,53: 255-263.
3[3]Ohnmacht GA,Marincola FM.Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma[J].J Cell Physiol,2000,182: 332-338.
4[4]Ikeda H,Lethe B,Lehmann F,et al.Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor[ J].Immunity,1997,6: 199-208.
5[5]Sykulev Y,Joo M,Vturina I,et al.Evidence that a single peptide-MHC complex on a target cell can elicit acytolytic T cell response[J].Immunity,1996,4: 565-571.
6[6]Pratap M,Jack LS.Perfusion chromatography for very rapid purification of class I and Ⅱ MHC proteins[ J].J Immunolo Methods,2000,234: 83-88.
7[7]Yuki N,Hiroeki S,Kazuhiro S,et al.Induction of CTL from peripheral blood of HLA-A31 + gastric cancer patients by in vitro stimulation with antigenic peptide of signet ring cell carcinoma[J].Jpn J Cancer Res,2000,91: 616-621.
8[8]Schirle M,Keilholz W,Weber B,et al.Identification of tumorassociated MHC class I Iigands by a novel T cell-independent approach[J].Eur J Immunol,2000,30(8): 2216-2225
9[9]Kessler JH,Beekman NJ,Bres-Vloemans SA,et al.Efficient identification of novel HLA-A ( * ) 0201 -presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis[ J].J Exp Med,2001,193(1): 73-88.
10[10]Lu J,Celis E.Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes [ J ].Cancer Res,2000,60(18): 5223-5227.
